Sulopenem etzadroxil is a Small Molecule owned by Iterum Therapeutics, and is involved in 9 clinical trials, of which 7 were completed, and 2 are ongoing.

Sulopenem etzadroxil (PF-03709270) acts inhibitor of penicillin binding protein (PBP). Cell wall is composed of a complex cross-linked polymer, peptidoglycan. Penems, like all beta-lactams, enter the bacterial cell and bind to Penicillin-binding proteins (PBPs), preventing bacterial cell wall synthesis. Penems have a higher affinity for many PBPs than do many other beta-lactams. PBPs catalyze the transpeptidase reaction that removes the terminal alanine to form a cross link with a nearby peptide, which gives cell wall its structural rigidity. Penems, like other beta-lactams, can cause morphologic changes to susceptible bacteria and bactericidal effects.

The revenue for Sulopenem etzadroxil is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sulopenem etzadroxil NPV Report.

Sulopenem etzadroxil was originated by Pfizer and is currently owned by Iterum Therapeutics.

Sulopenem etzadroxil Overview

Sulopenem etzadroxil (PF-03709270) is under development for the treatment of complicated urinary tract infections, uncomplicated urinary tract infections (uUTI), complicated intra-abdominal infections, community-acquired bacterial pneumonia, pelvic inflammatory disease and bacterial infections like acute bacterial prostatitis, gonococcal urethritis. The drug candidate is a penem beta-lactam antibiotic. It is administered through oral route. The drug candidate is a prodrug of sulopenam (CP-70,429). It acts by targeting penicillin binding protein (PBP).

Iterum Therapeutics Overview

Iterum Therapeutics is a clinical-stage pharmaceutical company. It develops anti-infectives for multi-drug resistant (MDR) pathogens for treating serious and life-threatening diseases. The company mainly develops Sulopenem, an oral and IV targeted-spectrum penem antibiotic for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community environments. Iterum Therapeutics seeks to work in partnership with other pharmaceutical companies for product development and commercialization opportunities. The company has operations with research and development facility in the US. Iterum Therapeutics is headquartered in Dublin, Ireland.

The operating loss of the company was US$24.5 million in FY2021, compared to an operating loss of US$34.6 million in FY2020. The net loss of the company was US$91.6 million in FY2021, compared to a net loss of US$52 million in FY2020.

Quick View – Sulopenem etzadroxil

Report Segments
  • Innovator
Drug Name
  • Sulopenem etzadroxil
Administration Pathway
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Companies
Highest Development Stage
  • Filing rejected/Withdrawn

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.